- Investing Ideas
- /
- Australian Pharmaceuticals & Biotech Healthy high growth potential
Australian Pharmaceuticals & Biotech Healthy high growth potential
Results
4
Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.
4 companies
Mesoblast
Market Cap: AU$2.9b
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
MSB
AU$2.30
7D
-0.4%
1Y
150.0%
Clinuvel Pharmaceuticals
Market Cap: AU$593.5m
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
CUV
AU$11.84
7D
8.7%
1Y
-21.0%
Immutep
Market Cap: AU$359.6m
A biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.
IMM
AU$0.24
7D
4.3%
1Y
-29.0%
PYC Therapeutics
Market Cap: AU$495.8m
A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.
PYC
AU$0.85
7D
-30.0%
1Y
-41.4%